Sentence examples for intermediate end from inspiring English sources

The developer might be prepared to include, say, 25 affordable homes on the site in question, all of them at the more expensive "intermediate" end of the affordable spectrum, but would prefer to provide funds for 50 affordable homes, including some for social rent, in another, cheaper, location.

All will be at the "intermediate" end of the affordable range, which can mean rents of up to 80% of local market rates - which are very high in that part of London - or affordable only to households with incomes approaching £80,000 a year seeking some type of shared ownership deal.

Squamous dysplasia, the accepted histological precursor for esophageal squamous cell carcinoma, represents a potentially modifiable intermediate end point for chemoprevention trials in high-risk populations.

A theoretical hydroelastic analysis of an axially loaded uniform Timoshenko beam, with intermediate end fixities, undergoing hydrodynamic impact-induced bottom slamming, is presented.

Objective: The purpose of this study was to compare the effects of two hormone replacement therapies on the intermediate end points of coronary heart disease and mammary gland hyperplasia in postmenopausal monkeys.

Oral precancerous lesions are used as intermediate end point biological markers to help screen potential chemopreventive agents that might have utility in the prevention of oral and pharyngeal cancers.

Accordingly, aortic stiffness is increasingly used as an intermediate end point in clinical trials (8, 9).

Moreover, they could give insights for the intermediate end points in clinical trials [ 56].

Research on biomarkers of particles and fibers of concern has already generated a large amount of data supporting the validity of intermediate end-points to assess changes before clinically apparent disease occurs.

The dependence of responses on the reduced proliferation underpins the value of Ki67 as an intermediate end-point for treatment benefit with multiple studies having found that relative effects on proliferation by different drugs in neoadjuvant trials match their relative impact on recurrence.

Early biomarkers for SMN risk are currently not available, but would be helpful to use as intermediate end-points in such trials.